Document Detail


Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
MedLine Citation:
PMID:  23154560     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non-small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion-positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.
Authors:
Daisuke Matsubara; Yoshihiko Kanai; Shumpei Ishikawa; Shiori Ohara; Taichiro Yoshimoto; Takashi Sakatani; Sachiko Oguni; Tomoko Tamura; Hiroaki Kataoka; Shunsuke Endo; Yoshinori Murakami; Hiroyuki Aburatani; Masashi Fukayama; Toshiro Niki
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  7     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-16     Completed Date:  2013-05-07     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1872-6     Citation Subset:  IM    
Affiliation:
Department of Pathology, Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  genetics*,  pathology
Animals
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Blotting, Western
Carcinoma, Non-Small-Cell Lung / drug therapy,  genetics*,  pathology
Cell Proliferation / drug effects
Cytoskeletal Proteins / genetics*
Female
Humans
Immunoenzyme Techniques
Lung Neoplasms / drug therapy,  genetics*,  pathology
Mice
Mice, Inbred NOD
Mice, SCID
Oncogene Proteins, Fusion / genetics*
Phosphorylation / drug effects
Piperidines / administration & dosage
Proto-Oncogene Proteins c-ret / genetics*
Quinazolines / administration & dosage
RNA, Messenger / genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Transplantation, Heterologous
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/CCDC6 protein, human; 0/Cytoskeletal Proteins; 0/N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0/Oncogene Proteins, Fusion; 0/Piperidines; 0/Quinazolines; 0/RNA, Messenger; EC 2.7.10.1/Proto-Oncogene Proteins c-ret; EC 2.7.10.1/RET protein, human; S65743JHBS/gefitinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy ...
Next Document:  The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for futu...